Gadolinium In The News

Gadolinium Based Contrast Agents Used in MRIs Get New FDA Black Box Warning

Today, the Food & Drug Administration (FDA) issued a “Dear Healthcare Professional” letter to inform practitioners of recent changes to the prescribing information for gadolinium based contrast agents used during Magnetic Resonance Imaging (MRA). The letter informs healthcare professionals that a black box warning, the FDA’s most serious type of warning, had been added to the product labels. The blackbox warns of the association between the use of gadolinium contrast agents and a rare disorder called Nephrogenic Systemic Fibrosis/ Nephrogenic Fibrosing Dermopathy (NSF/NSD). Continue

Nephrogenic Systemic Fibrosis Research Yields Few Clues Into Devastating Disease

Since 1997, medical science has been trying to solve the mystery of Nephrogenic Systemic Fibrosis (NSF). NSF, also known as Nephrogenic Fibrosing Dermopathy, is a rare and little understood disease that affects people with kidney problems. Since the first cases were documented, research into NSF has provided few clues into its cause, and even fewer as to its treatment. Continue

Gadolinium Contrast Used in MRA Can Cause NSF & NFD

Gadolinium contrast agents have long been used in Magnetic Resonance Imagining (MRA) to enhance the quality of images. But in some patients, Gadolinium can have a toxic affect, causing a condition known of Nephrogenic Systemic Fibrosis (NSF) Continue